| Previous Close | 1.62 |
| Open | 1.66 |
| Day High | 2.15 |
| Day Low | 1.65 |
| 52-Week High | 122.93 |
| 52-Week Low | 1.19 |
| Volume | 3.27M |
| Average Volume | 361,350 |
| Market Cap | 5M |
| PE | -0.08 |
| EPS | -23.26 |
| Moving Average 50 Days | 1.85 |
| Moving Average 200 Days | 22.65 |
| Change | 0.23 |
Data not available
BiomX Issues Statement Regarding Recent Common Stock Trading Activity
GlobeNewswire Inc.
Jan 27, 2026 6:41 PM GMT
NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued
BiomX Announces $3.0 Million Private Placement
GlobeNewswire Inc.
Dec 29, 2025 1:00 PM GMT
Proceeds to Support the Company’s Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic AlternativesNESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clin
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
GlobeNewswire Inc.
Dec 08, 2025 12:30 PM GMT
Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in BX011, its phage program for Staphylococcus aureus (S.